Michael Evans, PhD

Title(s)Professor, Radiology
SchoolSchool of Medicine
Address600 16th Street, #N572C
San Francisco CA 94158
Phone415-514-1292
PronounsHe/Him/His
ORCID ORCID Icon0000-0003-4947-1316 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Saint Mary's College of MarylandBA2001Chemistry
    The Scripps Research InstitutePhD2007Chemistry
    Memorial Sloan Kettering Cancer CenterPostdoctoral2013Human Oncology and Pathogenesis Program
    Collapse awards and honors
    Society of Nuclear Medicine and Molecular Imaging2024Sam Gambhir Trailblazer Award
    World Molecular Imaging Society2023Roger Tsien Award
    The Academy for Radiology and Biomedical Imaging Research2020Council of Distinguished Investigators
    Prostate Cancer Foundation2020  - 2021Challenge Award
    V Foundation2020  - 2023Translational Science Grant
    UCSF School of Pharmacy2020Dean's Apple Award for Teaching
    The LAM Foundation2019  - 2020Pilot Award
    American Cancer Society2017  - 2021Research Scholar Award
    American Brain Tumor Association2017  - 2018Discovery Award
    UCSF2016  - 2018Brain Tumor SPORE Developmental Research Project
    UCSF Academic Senate2016  - 2017Team Science Award
    Helen Diller Family Comprehensive Cancer Center2016  - 2017Precision Imaging of Cancer and Therapy Pilot Award
    DOD Prostate Cancer Research Program2015  - 2017Idea Development Award
    UCSF Academic Senate2014  - 2015Pilot Award
    Prostate Cancer Foundation2013  - 2016David H. Koch Young Investigator Award
    National Cancer Institute2012  - 2017Pathway to Independence Award
    Imaging and Radiation Sciences Brigde Program, MSKCC2012  - 2014Research Grant
    Imaging and Radiation Sciences Bridge Program, Memorial Sloan Kettering Cancer Center2011Research Award
    Brain Tumor Center of Memorial Sloan Kettering Cancer Center2011Research Award
    National Institutes of Health and Memorial Sloan Kettering Cancer Center2007  - 2010R25 Fellowship

    Collapse Overview 
    Collapse overview
    Michael Evans, PhD, is a Professor in Residence in the UCSF Department of Radiology and Biomedical Imaging. He is a chemical biologist with an interest in biomarker discovery with proteomics, nuclear medicine, theranostics, and molecular imaging. Dr. Evans earned a BA in Chemistry from St. Mary’s College of Maryland and he obtained his PhD in Organic Chemistry from The Scripps Research Institute (CA) under the supervision of Professor Benjamin Cravatt. This was followed by a postdoctoral fellowship in Molecular Imaging from the Memorial Sloan Kettering Cancer Center in New York under the supervision of Professors Charles Sawyers and Jason Lewis. In 2013, Dr. Evans accepted a faculty position at UCSF.

    Dr. Evans has published over 80 peer-reviewed articles, 40 meeting abstracts, and is a co-inventor on 13 patents pending or issued. Dr. Evans also is the principle investigator or co-PI on several human trials focused on new strategies for imaging and treating tumors with radiopharmaceuticals. He is a scientific co-founder and previously served on the scientific advisory board of ORIC Pharmaceuticals, Inc. He is a co-founder of Therapaint, Inc, Honeybear Biosciences, and Hap10, Inc. Dr. Evans is a member of the American Chemical Society, the Society of Nuclear Medicine and Molecular Imaging, and the World Molecular Imaging Society. He has been invited nationally and internationally to lecture about his research. Has been recognized with numerous honors, including a 2013 Young Investigator Award from the Prostate Cancer Foundation, a Pathway to Independence Award from the National Cancer Institute, a 2017 Research Scholar Award from the American Chemical Society, the 2023 Roger Tsien Award for excellence in chemical biology from the World Molecular Imaging Society, the 2024 Sam Gambhir Trailblazer award from the Society of Nuclear Medicine and Molecular Imaging, and he was a 2020 inductee to the Council of Distinguished Investigators in the Academy of Radiology and Biomedical Imaging Research.


    Expertise:
    Chemical Biology, Positron emission tomography, Targeted Radioligand Therapy, Organic Chemistry, Cancer Biology,

    Education and Training:
    • Bachelor of Art: St. Mary’s College, St. Mary’s City, Maryland - Chemistry
    • Doctor of Philosophy: The Scripps Research Institute, La Jolla, California - Organic Chemistry
    • Postdoctoral Fellowship: Memorial Sloan Kettering Cancer Center, New York - Molecular Imaging

    Collapse Research 
    Collapse research activities and funding
    Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications
    NIH R01EB029429Jul 1, 2021 - Mar 31, 2025
    Role: Principal Investigator
    New radiotracer development to study immune cell mobilization of granzyme proteolytic activity
    NIH R01AI161027Apr 20, 2021 - Mar 31, 2025
    Role: Principal Investigator
    Precision targeting of T cell cytotoxicity with PET
    NIH R01CA258297Mar 1, 2021 - Feb 28, 2026
    Role: Principal Investigator
    Detection of the glucocorticoid receptor with PET in treatment resistant castration resistant prostate cancer
    Department of Defense Prostate Cancer Research Program W81XWH-20-1-0354Jun 1, 2020 - May 31, 2023
    Role: Principal Investigator
    Precision Targeting of Castration-Resistant Prostate Cancer with a Novel Ferrous IronDependent Therapeutic Delivery and Tumor Imaging Strategy
    Prostate Cancer Research Program W81XWH-18-1-0763Oct 15, 2018 - Oct 14, 2021
    Role: co-Principal Investigator
    Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies
    NIH R01EB025207Jul 1, 2018 - Mar 31, 2022
    Role: Principal Investigator
    Development and translation of a novel radioligand to measure pathological changes in glucocorticoid receptor expression in the brain
    NIH R01MH115043Dec 1, 2017 - Nov 30, 2021
    Role: Principal Investigator
    Developing 68Ga-citrate PET/MR to distinguish viable tumor from psuedoprogression
    American Brain Tumor Association DG1700008Jul 31, 2017 - Jun 29, 2018
    Role: PI
    Development of a biomarker for imaging mTORC1 activity with PET
    American Cancer Society 130635-RSG-17-005-01-CCEJul 1, 2017 - Jun 30, 2021
    Role: PI
    Annotating MYC status in treatment resistant metastatic castration resistant prostate cancer with Gallium-68 citrate PET
    Department of Defense Prostate Cancer Research Program W81XWH-16-1-0469Aug 30, 2016 - Aug 31, 2019
    Role: Co-I
    Development of a radioligand to measure glucocorticoid receptor expression in enzalutamide resistant prostate cancer
    Department of Defense Prostate Cancer Research Program W81XWH-15-1-0552Sep 28, 2015 - Sep 29, 2017
    Role: PI
    Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin
    NIH R00CA172695Jan 1, 2014 - Dec 31, 2016
    Role: Principal Investigator
    Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET
    NIH R01CA176671Apr 1, 2013 - Mar 31, 2019
    Role: Co-Principal Investigator
    Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin
    NIH K99CA172695Jan 3, 2013 - Dec 31, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies. Cancer Res. 2025 Jan 15; 85(2):329-341. Pandey A, Rohweder PJ, Chan LM, Ongpipattanakul C, Chung DH, Paolella B, Quimby FM, Nguyen N, Verba KA, Evans MJ, Craik CS. PMID: 39656104; PMCID: PMC11733532.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    2. Millimeter-scale radioluminescent power for electronic sensors. iScience. 2025 Jan 17; 28(1):111686. Kandala AN, Wang S, Blecha JE, Wang YH, Lall RK, Niknejad AM, Seo Y, Evans MJ, Flavell RR, VanBrocklin HF, Anwar M. PMID: 39877069; PMCID: PMC11772980.
      View in: PubMed   Mentions:
    3. Imaging the Granzyme Mediated Host Immune Response to Viral and Bacterial Pathogens In Vivo Using Positron Emission Tomography. ACS Infect Dis. 2024 Jun 14; 10(6):2108-2117. Pandey A, Chopra S, Cleary SJ, López-Álvarez M, Quimby FM, Alanizi AAA, Sakhamuri S, Zhang N, Looney MR, Craik CS, Wilson DM, Evans MJ. PMID: 38819300.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    4. SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide Cancer Therapy. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1575-1584. Lee K, Lall R, Chopra S, Evans MJ, Maharbiz MM, Seo Y, Anwar M. PMID: 38122990.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    5. Dosimetry Reconstruction in Radiopharmaceutical Therapy Using a Sparse Network of External ?-Sensors. International Journal of Radiation Oncology • Biology • Physics. 2023 Oct 1; 117(2):s30-s31. Lall LR, Evans EM, Seo SY, Niknejad NA, Anwar AM. .
      View in: Publisher Site   Mentions:
    6. Chemoenzymatic Syntheses of Fluorine-18-Labeled Disaccharides from [18F] FDG Yield Potent Sensors of Living Bacteria In Vivo. J Am Chem Soc. 2023 08 16; 145(32):17632-17642. Sorlin AM, López-Álvarez M, Rabbitt SJ, Alanizi AA, Shuere R, Bobba KN, Blecha J, Sakhamuri S, Evans MJ, Bayles KW, Flavell RR, Rosenberg OS, Sriram R, Desmet T, Nidetzky B, Engel J, Ohliger MA, Fraser JS, Wilson DM. PMID: 37535945; PMCID: PMC10436271.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    7. Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects. ACS Cent Sci. 2023 Jun 28; 9(6):1241-1251. Klauser PC, Chopra S, Cao L, Bobba KN, Yu B, Seo Y, Chan E, Flavell RR, Evans MJ, Wang L. PMID: 37396859; PMCID: PMC10311652.
      View in: PubMed   Mentions: 16  
    8. Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from [ 18 F]FDG yield potent sensors of living bacteria in vivo. bioRxiv. 2023 May 20. Sorlin AM, López-Álvarez M, Rabbitt SJ, Alanizi AA, Shuere R, Bobba KN, Blecha J, Sakhamuri S, Evans MJ, Bayles KW, Flavell RR, Rosenberg OS, Sriram R, Desmet T, Nidetzky B, Engel J, Ohliger MA, Fraser JS, Wilson DM. PMID: 37293043; PMCID: PMC10245702.
      View in: PubMed   Mentions:
    9. Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer. Clin Cancer Res. 2023 04 03; 29(7):1232-1242. Chopra S, Trepka K, Sakhamuri S, Carretero-González A, Zhu J, Egusa E, Zhou J, Leung K, Zhao N, Hooshdaran N, Feng FY, Wells JA, Chou J, Evans MJ. PMID: 36648492; PMCID: PMC10073270.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    10. Preclinical evaluation of theranostic strategy using nanoplatform and transferrin to target hyperactivity of cMYC in the context of non-small cell lung cancer. Nuklearmedizin - NuclearMedicine. 2023 Mar 1; 47(2):51. Aubert AS, Richard RM, Kereselidze KD, Evans EM, Kuhnast KB, Porcel PE, Truillet TC. .
      View in: Publisher Site   Mentions:
    11. Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy. Eur J Med Chem. 2023 Mar 05; 249:115110. Gonciarz RL, Sakhamuri S, Hooshdaran N, Kumar G, Kim H, Evans MJ, Renslo AR. PMID: 36708680; PMCID: PMC10210592.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    12. Avalanche Photodiode-Based ?-Photon Scintillation Detectors for Personalized Dosimetry in Targeted Radionuclide Therapy. International Journal of Radiation Oncology • Biology • Physics. 2022 Nov 1; 114(3):e530-e531. Lall LR, Lee LK, Chopra CS, Niknejad NA, Evans EM, Anwar AM. .
      View in: Publisher Site   Mentions:
    13. Personalized Lu177 Theranostic Dosimetry Using a Single Beta-Particle In Vivo Microdosimeter. International Journal of Radiation Oncology • Biology • Physics. 2022 Nov 1; 114(3):s125. Lee LK, Lall LR, Chopra CS, Maharbiz MM, Evans EM, Anwar AM. .
      View in: Publisher Site   Mentions:
    14. Impact of Radiolabeling Strategies on the Pharmacokinetics and Distribution of an Anti-PD-L1 PET Ligand. Mol Pharm. 2022 10 03; 19(10):3673-3680. Tran VL, Bouleau A, Nozach H, Richard M, Chevaleyre C, Dubois S, Kereselidze D, Kuhnast B, Evans MJ, Specklin S, Truillet C. PMID: 35998011.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    15. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clin Cancer Res. 2022 07 15; 28(14):3066-3075. Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ. PMID: 35604681; PMCID: PMC9288514.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    16. Defining the Magnetic Resonance Features of Renal Lesions and Their Response to Everolimus in a Transgenic Mouse Model of Tuberous Sclerosis Complex. Front Oncol. 2022; 12:851192. Agarwal S, Decavel-Bueff E, Wang YH, Qin H, Santos RD, Evans MJ, Sriram R. PMID: 35814396; PMCID: PMC9260108.
      View in: PubMed   Mentions:
    17. Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors. J Exp Med. 2022 04 04; 219(4). Jiang H, Muir RK, Gonciarz RL, Olshen AB, Yeh I, Hann BC, Zhao N, Wang YH, Behr SC, Korkola JE, Evans MJ, Collisson EA, Renslo AR. PMID: 35262628; PMCID: PMC8916116.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    18. Switchable assembly and function of antibody complexes in vivo using a small molecule. Proc Natl Acad Sci U S A. 2022 03 01; 119(9). Martinko AJ, Simonds EF, Prasad S, Ponce A, Bracken CJ, Wei J, Wang YH, Chow TL, Huang Z, Evans MJ, Wells JA, Hill ZB. PMID: 35210365; PMCID: PMC8892515.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. J Clin Invest. 2022 02 15; 132(4). Lim SA, Zhou J, Martinko AJ, Wang YH, Filippova EV, Steri V, Wang D, Remesh SG, Liu J, Hann B, Kossiakoff AA, Evans MJ, Leung KK, Wells JA. PMID: 35166238; PMCID: PMC8843743.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    20. In Vivo Profiling with 18F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions. Mol Pharm. 2022 02 07; 19(2):704-709. Kim H, Huang Y, Zhao N, Wang YH, Sakhamuri S, Chopra S, Hooshdaran N, Sriram R, Aggarwal R, Evans MJ. PMID: 35049307.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology. Methods Mol Biol. 2022; 2393:829-839. Wei J, Oh DY, Evans MJ. PMID: 34837214.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    22. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats. J Nucl Med. 2022 08; 63(8):1259-1265. Bouleau A, Nozach H, Dubois S, Kereselidze D, Chevaleyre C, Wang CI, Evans MJ, Lebon V, Maillère B, Truillet C. PMID: 34933891; PMCID: PMC9364342.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    23. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen. ACS Appl Mater Interfaces. 2021 Nov 24; 13(46):54739-54752. Meher N, Seo K, Wang S, Bidkar AP, Fogarty M, Dhrona S, Huang X, Tang R, Blaha C, Evans MJ, Raleigh DR, Jun YW, VanBrocklin HF, Desai TA, Wilson DM, Ozawa T, Flavell RR. PMID: 34752058.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    24. In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. ACS Cent Sci. 2021 Oct 27; 7(10):1638-1649. Zhao N, Bardine C, Lourenço AL, Wang YH, Huang Y, Cleary SJ, Wilson DM, Oh DY, Fong L, Looney MR, Evans MJ, Craik CS. PMID: 34729407; PMCID: PMC8554823.
      View in: PubMed   Mentions: 26  
    25. Quantitative Tissue Pharmacokinetics and EPR Effect of AGuIX Nanoparticles: A Multimodal Imaging Study in an Orthotopic Glioblastoma Rat Model and Healthy Macaque. Adv Healthc Mater. 2021 08; 10(16):e2100656. Tran VL, Lux F, Tournier N, Jego B, Maître X, Anisorac M, Comtat C, Jan S, Selmeczi K, Evans MJ, Tillement O, Kuhnast B, Truillet C. PMID: 34212539.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    26. Feasibility study of gallium-68 citrate PET as a bone-tropic imaging biomarker in mCRPC. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):31-31. de Kouchkovsky dI, Behr BS, Zhang ZL, Foye FA, Vanbrocklin VH, Small SE, Feng FF, Friedlander FT, Li LP, Frey FN, Chung CA, Lui LA, Subramanian SA, Rodvelt RT, Barlesi BB, Evans EM, Aggarwal AR. .
      View in: Publisher Site   Mentions:
    27. Synthesis and Screening of α-Xylosides in Human Glioblastoma Cells. Mol Pharm. 2021 01 04; 18(1):451-460. Kalita M, Villanueva-Meyer J, Ohkawa Y, Kalyanaraman C, Chen K, Mohamed E, Parker MFL, Jacobson MP, Phillips JJ, Evans MJ, Wilson DM. PMID: 33315406; PMCID: PMC8483608.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    28. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clin Cancer Res. 2021 03 01; 27(5):1305-1315. Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J. PMID: 33293372; PMCID: PMC7925362.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    29. Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies. J Nucl Med. 2021 Jul 01; 62(7):949-955. Zhao N, Huang Y, Wang YH, Muir RK, Chen YC, Wei J, Hooshdaran N, Viswanath P, Seo Y, Ruggero D, Renslo AR, Evans MJ. PMID: 33246980; PMCID: PMC8882888.
      View in: PubMed   Mentions: 25     Fields:    Translation:Animals
    30. The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (±)-11C-YJH08 PET. J Nucl Med. 2021 05 10; 62(5):723-731. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Parker MFL, Blecha JE, Drake CR, VanBrocklin HF, Garrido-Ruiz D, Jacobson MP, Aggarwal R, Behr SC, Flavell RR, Wilson DM, Seo Y, Evans MJ. PMID: 32887758; PMCID: PMC8844266.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    31. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Mol Imaging Biol. 2020 12; 22(6):1553-1561. Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. PMID: 32813112; PMCID: PMC7669684.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    32. Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):242-257. Flavell RR, Evans MJ, Villanueva-Meyer JE, Yom SS. PMID: 32585333.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    33. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clin Cancer Res. 2020 07 15; 26(14):3608-3615. Moroz A, Wang YH, Sharib JM, Wei J, Zhao N, Huang Y, Chen Z, Martinko AJ, Zhuo J, Lim SA, Zhang LH, Seo Y, Carlin S, Leung KK, Collisson EA, Kirkwood KS, Wells JA, Evans MJ. PMID: 32341034; PMCID: PMC7367754.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    34. A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chem Biol. 2020 06 19; 15(6):1381-1391. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Blecha JE, VanBrocklin HF, Seo Y, Sayeed M, Feldman BJ, Aggarwal R, Behr SC, Shao H, Wilson DM, Villanueva-Meyer JE, Gestwicki JE, Evans MJ. PMID: 32255605; PMCID: PMC8031368.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    35. Arabinofuranose-derived positron-emission tomography radiotracers for detection of pathogenic microorganisms. J Labelled Comp Radiopharm. 2020 May 15; 63(5):231-239. Kalita M, Parker MFL, Luu JM, Stewart MN, Blecha JE, VanBrocklin HF, Evans MJ, Flavell RR, Rosenberg OS, Ohliger MA, Wilson DM. PMID: 32222086; PMCID: PMC7364301.
      View in: PubMed   Mentions: 4     Fields:    Translation:Cells
    36. Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. Mol Imaging Biol. 2020 02; 22(1):208-216. Seo Y, Khalighi MM, Wangerin KA, Deller TW, Wang YH, Jivan S, Kohi MP, Aggarwal R, Flavell RR, Behr SC, Evans MJ. PMID: 30993558; PMCID: PMC6800603.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    37. Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling. Mol Cell Proteomics. 2020 02; 19(2):294-307. Wei J, Leung K, Truillet C, Ruggero D, Wells JA, Evans MJ. PMID: 31792071; PMCID: PMC7000124.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    38. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy. Mol Pharm. 2019 09 03; 16(9):3831-3841. Wang S, Blaha C, Santos R, Huynh T, Hayes TR, Beckford-Vera DR, Blecha JE, Hong AS, Fogarty M, Hope TA, Raleigh DR, Wilson DM, Evans MJ, VanBrocklin HF, Ozawa T, Flavell RR. PMID: 31381351; PMCID: PMC6722010.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    39. Abstract 550: Tumor-conditional anti-CTLA-4 uncouples anti-tumor efficacy from immunotherapy-related toxicity. Cancer Research. 2019 Jul 1; 79(13_Supplement):550-550. Pai PS, Simons SD, Lu LX, Ritacco RW, Evans EM, Kingsbury KG, Fong FL. .
      View in: Publisher Site   Mentions:
    40. Measuring Dynamic Changes in the Labile Iron Pool in Vivo with a Reactivity-Based Probe for Positron Emission Tomography. ACS Cent Sci. 2019 Apr 24; 5(4):727-736. Muir RK, Zhao N, Wei J, Wang YH, Moroz A, Huang Y, Chen YC, Sriram R, Kurhanewicz J, Ruggero D, Renslo AR, Evans MJ. PMID: 31041393; PMCID: PMC6487455.
      View in: PubMed   Mentions: 21  
    41. Enzymatically Catalyzed Radiofluorination of Biomolecules. Methods Mol Biol. 2019; 2033:191-205. Drake CR, Evans MJ, VanBrocklin HF. PMID: 31332755.
      View in: PubMed   Mentions:    Fields:    Translation:Cells
    42. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Invest. 2019 01 02; 129(1):349-363. Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, Chen M, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, Bousquet P, Mankovich J, Kingsbury G, Fong L. PMID: 30530991; PMCID: PMC6307943.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansAnimalsCells
    43. Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight. 2018 11 02; 3(21). Behr SC, Villanueva-Meyer JE, Li Y, Wang YH, Wei J, Moroz A, Lee JK, Hsiao JC, Gao KT, Ma W, Cha S, Wilson DM, Seo Y, Nelson SJ, Chang SM, Evans MJ. PMID: 30385712; PMCID: PMC6238742.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    44. A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4. Bioconjug Chem. 2018 10 17; 29(10):3476-3482. Moroz A, Lee CY, Wang YH, Hsiao JC, Sevillano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ. PMID: 30227708; PMCID: PMC6430562.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    45. AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br J Radiol. 2019 Jan; 92(1093):20180365. Lux F, Tran VL, Thomas E, Dufort S, Rossetti F, Martini M, Truillet C, Doussineau T, Bort G, Denat F, Boschetti F, Angelovski G, Detappe A, Crémillieux Y, Mignet N, Doan BT, Larrat B, Meriaux S, Barbier E, Roux S, Fries P, Müller A, Abadjian MC, Anderson C, Canet-Soulas E, Bouziotis P, Barberi-Heyob M, Frochot C, Verry C, Balosso J, Evans M, Sidi-Boumedine J, Janier M, Butterworth K, McMahon S, Prise K, Aloy MT, Ardail D, Rodriguez-Lafrasse C, Porcel E, Lacombe S, Berbeco R, Allouch A, Perfettini JL, Chargari C, Deutsch E, Le Duc G, Tillement O. PMID: 30226413; PMCID: PMC6435081.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansAnimals
    46. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clin Cancer Res. 2019 01 01; 25(1):166-176. Henry KE, Dacek MM, Dilling TR, Caen JD, Fox IL, Evans MJ, Lewis JS. PMID: 30228208; PMCID: PMC6320277.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    47. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2045-2054. Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U. PMID: 29980832; PMCID: PMC6182397.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    48. Abstract 3694: Measuring oncogene signaling with transferrin-based PET: From bench to bedside. Clinical Research (Excluding Clinical Trials). 2018 Jul 1; 3694-3694. Evans EM, Truillet TC, Ruggero RD, Lewis LJ, Aggarwal AR, Behr BS. .
      View in: Publisher Site   Mentions:
    49. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):78-82. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. PMID: 31100231.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    50. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018 05 02; 10(439). Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. PMID: 29720449; PMCID: PMC6045425.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansAnimalsCells
    51. PET imaging of tumor PD-L1 expression with 89Zr-labeled anti-PD-L1 antibodies. Nuklearmedizin. 2018 May 1; 42(3):158. Truillet TC, Sevillano SN, Jego JB, Jaumain JE, Craik CC, Wang WC, Evans EM. .
      View in: Publisher Site   Mentions:
    52. Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget. 2018 Apr 17; 9(29):20399-20408. Truillet C, Parker MFL, Huynh LT, Wei J, Jami KM, Wang YH, Shen YS, Sriram R, Wilson DM, Kurhanewicz J, Evans MJ. PMID: 29755660; PMCID: PMC5945515.
      View in: PubMed   Mentions: 4     Fields:    
    53. Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife. 2018 01 23; 7. Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA. PMID: 29359686; PMCID: PMC5796798.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    54. Imaging PD-L1 Expression with ImmunoPET. Bioconjug Chem. 2018 01 17; 29(1):96-103. Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. PMID: 29125731; PMCID: PMC5773933.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    55. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen. ACS Chem Biol. 2017 12 15; 12(12):2934-2939. de Jesus Cortez F, Nguyen P, Truillet C, Tian B, Kuchenbecker KM, Evans MJ, Webb P, Jacobson MP, Fletterick RJ, England PM. PMID: 28981251.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    56. Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. Genes Dev. 2017 10 15; 31(20):2067-2084. Lue HW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburg KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, Anderson KE, Evans MJ, O'Donnell VB, Nomura DK, Drake JM, Ritz A, Thomas GV. PMID: 29138276; PMCID: PMC5733498.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    57. Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer. J Nucl Med. 2018 01; 59(1):51-57. Henry KE, Dilling TR, Abdel-Atti D, Edwards KJ, Evans MJ, Lewis JS. PMID: 28848040; PMCID: PMC5750524.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    58. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 09; 15(9):1221-1229. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. PMID: 28592703; PMCID: PMC5581675.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    59. Abstract A25: Sensing stress in cancer: a novel therapy targeting protein synthesis through the unfolded protein response in prostate cancer development. Translation Control: an Adaptive Response to Oncogenic Cellular Stress. 2017 Mar 15; a25-a25. Conn CC, Nguyen NH, Kye KY, Cunningham CJ, Truillet TC, Evans EM, Huynh HT, Walters WP, Ruggero RD. .
      View in: Publisher Site   Mentions:
    60. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. Mol Imaging. 2017 Jan-Dec; 16:1536012117723256. Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ. PMID: 28893116; PMCID: PMC5598799.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    61. Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin. Clin Cancer Res. 2017 Jun 15; 23(12):3045-3052. Truillet C, Cunningham JT, Parker MFL, Huynh LT, Conn CS, Ruggero D, Lewis JS, Evans MJ. PMID: 28007777; PMCID: PMC5474159.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    62. A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 12; 18(6):946-951. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ. PMID: 27184068; PMCID: PMC6430569.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    63. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017 Jan; 58(1):81-84. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. PMID: 27660139; PMCID: PMC5209643.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansAnimalsCells
    64. Synthesis and Characterization of (89)Zr-Labeled Ultrasmall Nanoparticles. Mol Pharm. 2016 07 05; 13(7):2596-601. Truillet C, Thomas E, Lux F, Huynh LT, Tillement O, Evans MJ. PMID: 27266800; PMCID: PMC6430584.
      View in: PubMed   Mentions: 7     Fields:    Translation:Animals
    65. A reactivity-based [18F]FDG probe for in vivo formaldehyde imaging using positron emission tomography. Chem Sci. 2016 Aug 01; 7(8):5503-5507. Liu W, Truillet C, Flavell RR, Brewer TF, Evans MJ, Wilson DM, Chang CJ. PMID: 30034690; PMCID: PMC6021783.
      View in: PubMed   Mentions: 13  
    66. Site-Specific Radiofluorination of Biomolecules with 8-[(18)F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chem Biol. 2016 06 17; 11(6):1587-94. Drake CR, Sevillano N, Truillet C, Craik CS, VanBrocklin HF, Evans MJ. PMID: 27008570; PMCID: PMC5712215.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    67. [(11)C]Ascorbic and [(11)C]dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chem Commun (Camb). 2016 Apr 07; 52(27):4888-90. Carroll VN, Truillet C, Shen B, Flavell RR, Shao X, Evans MJ, VanBrocklin HF, Scott PJ, Chin FT, Wilson DM. PMID: 26963495; PMCID: PMC4854297.
      View in: PubMed   Mentions: 25     Fields:    Translation:Cells
    68. A Reactivity-Based [18F]FDG Probe for In Vivo Formaldehyde Imaging Using Positron Emission Tomography. Chemical Science. 2016; (7):5503-5507. Liu, W.; Truillet, C.; Flavell, R.R.; Brewer, T.; Evans, M.J.; Wilson, D.M.; Chang, C.
    69. 11C-Ascorbic and 11C-dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chemical Communications. 2016; 27(52):4888-4890. Carroll, V.N.; Truillet, C.; Shen, B.; Flavell, R.R.; Shao, X.; Evans, M.J.; VanBrocklin, H.F.; Scott, P.H.J.; Chin, F.T.; Wilson, D.M.
    70. Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Mol Pharm. 2016 Feb 01; 13(2):683-8. Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ. PMID: 26725682; PMCID: PMC4738321.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    71. Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjug Chem. 2016 Jan 20; 27(1):170-8. Flavell RR, Truillet C, Regan MK, Ganguly T, Blecha JE, Kurhanewicz J, VanBrocklin HF, Keshari KR, Chang CJ, Evans MJ, Wilson DM. PMID: 26649808; PMCID: PMC4854293.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    72. Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res. 2015 Nov 15; 75(22):4688-96. Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL. PMID: 26432404; PMCID: PMC4651750.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsCells
    73. Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. Eur Urol. 2015 Dec; 68(6):1076-82. Gerdtsson A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, Abrahamsson PA, Nilsson P, Manjer J, Bjartell A, Malm J, Vickers A, Freedland SJ, Lilja H, Ulmert D. PMID: 25794458; PMCID: PMC4573834.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    74. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. J Nucl Med. 2014 Dec; 55(12):2045-9. Doran MG, Watson PA, Cheal SM, Spratt DE, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS. PMID: 25453051; PMCID: PMC4410715.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    75. Cabozantinib Resolves Bone Scans in Tumor-Naïve Mice Harboring Skeletal Injuries. Mol Imaging. 2014 Oct 01; 13(8):7290201400026. Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ. PMID: 28650280.
      View in: PubMed   Mentions:
    76. 89Zr-MSTP2109A, A Novel Antibody Based Radiotracer to Evaluate and Guide the Clinical Translation of Antibody-Drug Conjugates Targeting STEAP1. International Journal of Radiation Oncology • Biology • Physics. 2014 Sep 1; 90(1):s791. Spratt SD, Doran DM, Wongvipat WJ, Lewis LJ, Evans EM. .
      View in: Publisher Site   Mentions:
    77. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014 Aug 15; 28(16):1800-14. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. PMID: 25128497; PMCID: PMC4197965.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansAnimalsCells
    78. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):985-94. Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM. PMID: 24604591; PMCID: PMC4120276.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    79. Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Mol Imaging. 2014; 13. Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ. PMID: 25248353; PMCID: PMC4545649.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    80. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. Inorg Chem. 2014 Feb 17; 53(4):1880-99. Zeglis BM, Houghton JL, Evans MJ, Viola-Villegas N, Lewis JS. PMID: 24313747; PMCID: PMC4151561.
      View in: PubMed   Mentions: 33     Fields:    Translation:Animals
    81. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med. 2013 Nov; 54(11):1876-82. Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak KK, Drobjnak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. PMID: 24029655; PMCID: PMC4274751.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    82. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb Haemost. 2013 Sep; 110(3):484-92. Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H. PMID: 23903407; PMCID: PMC4029064.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    83. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013 Apr 09; 2:e00499. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. PMID: 23580326; PMCID: PMC3622181.
      View in: PubMed   Mentions: 184     Fields:    Translation:HumansCells
    84. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. Mol Imaging. 2013 Jan-Feb; 12(1):67-73. Stelter L, Evans MJ, Jungbluth AA, Longo VA, Zanzonico P, Ritter G, Bomalaski JS, Old L, Larson SM. PMID: 23348793.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    85. Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med. 2013 Jan; 54(1):90-5. Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL, Lewis JS. PMID: 23236019; PMCID: PMC3747823.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    86. Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov. 2012 Nov; 2(11):985-94. Evans MJ. PMID: 23043150; PMCID: PMC3508522.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    87. Annotating MYC status with 89Zr-transferrin imaging. Nat Med. 2012 Oct; 18(10):1586-91. Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. PMID: 23001181; PMCID: PMC3521603.
      View in: PubMed   Mentions: 41     Fields:    Translation:Animals
    88. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012 Apr; 2(4):320-7. Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL. PMID: 22576209; PMCID: PMC3351274.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    89. Abstract IA22: Molecular Imaging of androgen receptor signalling in CRPC. Cancer Research. 2012 Feb 6; 72(4 Supplement):ia22-ia22. Larson LS, Fox FJ, Morris MM, Evans EM, Lewis LJ, Humm HJ, Sawyers SC, Scher SH. .
      View in: Publisher Site   Mentions:
    90. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012 Jul; 62(1):78-84. Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM. PMID: 22306323; PMCID: PMC3402084.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    91. Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma. J Nucl Med. 2012 Feb; 53(2):281-6. Stelter L, Evans MJ, Jungbluth AA, Zanzonico P, Ritter G, Ku T, Rosenfeld E, Bomalaski JS, Old L, Larson SM. PMID: 22228793.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    92. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011 Jun 07; 108(23):9578-82. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL. PMID: 21606347; PMCID: PMC3111331.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansAnimalsCells
    93. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A. 2010 Apr 06; 107(14):6459-64. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK. PMID: 20308550; PMCID: PMC2851999.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    94. Abstract B207: Prostate specific membrane antigen is a diagnostic marker of response to allosteric androgen receptor inhibition. Molecular Cancer Therapeutics. 2009 Dec 10; 8(12_Supplement):b207-b207. Evans EM, Smith-Jones SP, Wongvipat WJ, Larson LS, Sawyers SC. .
      View in: Publisher Site   Mentions:
    95. Polyanionic gallium hydrides from AlB2-type precursors AeGaE (Ae = Ca, Sr, Ba; E = Si, Ge, Sn). J Am Chem Soc. 2008 Sep 10; 130(36):12139-47. Evans MJ, Holland GP, Garcia-Garcia FJ, Häussermann U. PMID: 18698774.
      View in: PubMed   Mentions: 1     Fields:    
    96. Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides. Mol Biosyst. 2007 Jul; 3(7):495-506. Evans MJ, Morris GM, Wu J, Olson AJ, Sorensen EJ, Cravatt BF. PMID: 17579775.
      View in: PubMed   Mentions: 12     Fields:    
    97. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007 Feb 01; 445(7127):541-5. Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, Patapoutian A. PMID: 17237762.
      View in: PubMed   Mentions: 489     Fields:    Translation:HumansAnimalsCells
    98. Mechanism-based profiling of enzyme families. Chem Rev. 2006 Aug; 106(8):3279-301. Evans MJ, Cravatt BF. PMID: 16895328.
      View in: PubMed   Mentions: 132     Fields:    
    99. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol. 2005 Oct; 23(10):1303-7. Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF. PMID: 16200062.
      View in: PubMed   Mentions: 71     Fields:    
    Michael's Networks
    Concepts (359)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (70)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-13-gbc789823 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.